RE:RE:RE:ONCY Anticipated Milestones and Catalysts Q4 ' 2021AWARE-1 data reported in April 2021 - while ONCY has stated in it's September 2021 corporate presentation that the final biomarker data on the AWARE -1 was expected in H2 2021 the below reference press release makes no mention of the final biomarker data. ONCY's messaging has been certainly confusing.
Oncolytics Biotech® and SOLTI Achieve Primary Endpoint in AWARE-1 Study
- Pelareorep and atezolizumab synergize the anti-cancer immune response in HR+/HER2- breast cancer patients
- Pelareorep alone and with checkpoint blockade converts tumors to PD-L1 positive classification
- Oncolytics validates that pelareorep significantly improves immunotherapies
SAN DIEGO and CALGARY, Alberta, April 12, 2021 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), together with SOLTI, recently announced new clinical data from the AWARE-1 window-of-opportunity breast cancer study showing patients receiving pelareorep plus checkpoint blockade therapy met the trial's primary endpoint. These data are featured in an electronic poster at the American Association for Cancer Research (AACR) Annual Meeting 2021 during Week 1, which is taking place virtually from April 10-15, 2021.
https://d1io3yog0oux5.cloudfront.net/_99386313223d876522c05506118aff1d/oncolyticsbiotech/db/300/2536/pdf/Oncolytics+Corporate+Presentation+September.pdf